Qu Biologics Inc., a biopharmaceutical company focused on developing Site Specific Immunomodulators (SSIs) to enhance innate immune function, has partnered with Foundation Medicine, Inc. This collaboration aims to improve treatment for patients with late-stage colorectal cancer undergoing surgery.

Qu Biologics is running a Phase II multicenter, randomized, placebo-controlled trial (PERIOP-06) to assess QBECO SSI's ability to reduce post-operative immune suppression and improve cancer outcomes in patients undergoing surgical removal of liver metastases. Foundation Medicine will perform genomic and transcriptomic profiling for trial participants, aiding in the prediction of responses to Qu’s innovative immunotherapy and monitoring minimal residual disease over time. The study will investigate the correlations between Foundation Medicine’s genomic profiling results, changes in patients’ immune function with QBECO SSI, and their progression-free and overall survival rates.

The PERIOP-06 trial is led by GI Oncology surgeons Dr. Rebecca Auer (Executive Vice-President of Research and Innovation at Ottawa Hospital and CEO of Ottawa Hospital’s Research Institute) and Dr. Paul Karanicolas (Co-Director of the Centre for Clinical Trial Support at Sunnybrook Health Sciences Centre). Patient enrollment is currently underway at academic oncology centers in Ontario.

Qu Biologics, highlighted the importance of the partnership: “This research will not only help identify which cancer patients are most likely to benefit from peri-operative QBECO SSI treatment, but it is also expected to foster a long-term collaboration with Foundation Medicine. This will support monitoring disease progression in future pivotal studies, speeding up the approval and broader availability of QBECO SSI.”

Dr. Auer expressed enthusiasm for the partnership, stating, “When patients participate in a clinical trial, we have a responsibility to maximize the knowledge gained from the biospecimens collected. It is exciting to be involved in a study with such significant learning potential.”

 

Source: globenewswire.com

Report Abuse